Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

NXP-031 leads to significant improvement of motor deficit in MPTP-induced mouse model of PD

Nov. 6, 2019

Cartesian initiates phase I/II study of its lead CAR-T candidate, Descartes-08

Nov. 6, 2019

Tau spreads quickly but kills slowly

Nov. 6, 2019

Japanese investigators patent CRF1 and CRF2 dual receptor antagonists

Nov. 5, 2019

Neuronal insulin resistance linked to age-related dementia

Nov. 4, 2019

Oligomannate approved in China for mild to moderate AD

Nov. 4, 2019

Promentis Pharmaceuticals announces update on phase II development of SXC-2023

Nov. 4, 2019

NTS2-selective compounds with promising activity in preclinical models of pain

Nov. 4, 2019

ACADIA Pharmaceuticals initiates phase III LAVENDER study of trofinetide in Rett syndrome

Oct. 31, 2019

FDA approves Vumerity for the treatment of multiple sclerosis

Oct. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...